Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its shareholding in Xeris Biopharma by 2.7%, acquiring an additional 210,581 shares, bringing its total ownership to approximately 5.19% of the company, valued at $44.5 million.
• Numerous institutional investors, including Millennium Management and Essex Investment Management, have significantly boosted their stakes in Xeris Biopharma, highlighting strong hedge fund interest in the company.
• Xeris Biopharma recently reported earnings of ($0.01) per share, beating estimates, with a quarterly revenue of $67.71 million, exceeding expectations of $64.58 million.

Vanguard Group Inc. boosted its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 2.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,109,644 shares of the company's stock after buying an additional 210,581 shares during the period. Vanguard Group Inc. owned approximately 5.19% of Xeris Biopharma worth $44,522,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its position in Xeris Biopharma by 92.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock valued at $172,000 after buying an additional 14,986 shares during the last quarter. Millennium Management LLC grew its position in Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after buying an additional 502,853 shares during the last quarter. Two Sigma Advisers LP purchased a new position in Xeris Biopharma in the 4th quarter valued at $47,000. Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the 4th quarter valued at $45,000. Finally, CWM LLC grew its position in Xeris Biopharma by 79.3% in the 1st quarter. CWM LLC now owns 66,972 shares of the company's stock valued at $368,000 after buying an additional 29,614 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on XERS. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 19th. HC Wainwright started coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price on the stock. Finally, Oppenheimer boosted their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Xeris Biopharma has an average rating of "Moderate Buy" and a consensus price target of $7.08.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS traded down $0.07 during trading on Friday, hitting $7.83. 1,513,967 shares of the company were exchanged, compared to its average volume of 3,506,781. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -37.28 and a beta of 0.12. Xeris Biopharma Holdings, Inc. has a 1 year low of $2.48 and a 1 year high of $8.02. The firm's fifty day moving average price is $5.87 and its 200 day moving average price is $5.01.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Transactions at Xeris Biopharma

In other news, insider Kevin Mcculloch purchased 25,000 shares of the business's stock in a transaction dated Friday, June 13th. The stock was acquired at an average price of $4.38 per share, with a total value of $109,500.00. Following the purchase, the insider directly owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. This represents a 1.48% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Dawn Halkuff sold 42,500 shares of Xeris Biopharma stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total value of $309,400.00. Following the transaction, the director directly owned 115,000 shares of the company's stock, valued at $837,200. This trade represents a 26.98% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 192,232 shares of company stock worth $1,430,777. Corporate insiders own 4.56% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.